DRMAW
Price:
$0.011
Market Cap:
$2.32M
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.[Read more]
Industry
Biotechnology
IPO Date
2021-08-13
Stock Exchange
NASDAQ
Ticker
DRMAW
According to Dermata Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 7.11. This represents a change of 53.54% compared to the average of 4.63 of the last 4 quarters.
The mean historical Current Ratio of Dermata Therapeutics, Inc. over the last ten years is 4.29. The current 7.11 Current Ratio has changed 16.47% with respect to the historical average. Over the past ten years (40 quarters), DRMAW's Current Ratio was at its highest in in the June 2023 quarter at 12.76. The Current Ratio was at its lowest in in the March 2020 quarter at 0.
Average
4.29
Median
4.91
Minimum
0.16
Maximum
7.66
Discovering the peaks and valleys of Dermata Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 4.69%
Maximum Annual Current Ratio = 7.66
Minimum Annual Increase = -86.65%
Minimum Annual Current Ratio = 0.16
Year | Current Ratio | Change |
---|---|---|
2023 | 4.91 | -34.71% |
2022 | 7.53 | -1.78% |
2021 | 7.66 | 4.69% |
2020 | 0.16 | -86.65% |
The current Current Ratio of Dermata Therapeutics, Inc. (DRMAW) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
6.70
5-year avg
4.29
10-year avg
4.29
Dermata Therapeutics, Inc.’s Current Ratio is greater than eFFECTOR Therapeutics, Inc. (1.03), greater than NLS Pharmaceutics AG (0.15), less than Dermata Therapeutics, Inc. (7.11), less than Pasithea Therapeutics Corp. (14.81), greater than ZIVO Bioscience, Inc. (0.17),
Company | Current Ratio | Market cap |
---|---|---|
1.03 | $2.82K | |
0.15 | $8.19M | |
7.11 | $2.32M | |
14.81 | $4.04M | |
0.17 | $105.50M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Dermata Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Dermata Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Dermata Therapeutics, Inc.'s Current Ratio?
How is the Current Ratio calculated for Dermata Therapeutics, Inc. (DRMAW)?
What is the highest Current Ratio for Dermata Therapeutics, Inc. (DRMAW)?
What is the 3-year average Current Ratio for Dermata Therapeutics, Inc. (DRMAW)?
What is the 5-year average Current Ratio for Dermata Therapeutics, Inc. (DRMAW)?
How does the current Current Ratio for Dermata Therapeutics, Inc. (DRMAW) compare to its historical average?